论文部分内容阅读
目的:观察祛瘀汤对非小细胞肺癌患者血液高凝状态的影响。方法:将118例非小细胞肺癌患者随机分为2组各59例,对照组给予常规化疗治疗,研究组在对照组的基础上给予祛瘀汤内服。比较2组患者在凝血功能指标[(凝血酶原时间(PT)、纤维蛋白原(Fib)、血小板计数(BPC)、部分凝血活酶时间(APTT)]、临床疗效及不良反应。结果:治疗后研究组PT、APTT水平升高,BPC、Fib水平降低,与同组治疗前及对照组治疗后比较,差异均有统计学意义(P<0.05)。研究组患者临床疗效改善率为84.7%,对照组为59.3%,2组比较,差异有统计学意义(P<0.05)。研究组胃肠道反应率、肾功能异常率分别为44.1%、3.4%,对照组分别为71.2%、15.3%,2组比较,差异均有统计学意义(P<0.05)。结论:祛瘀汤治疗非小细胞肺癌能改善患者血液高凝状态,缓解临床症状,降低副反应率。
Objective: To observe the effect of Quyu Decoction on blood hypercoagulability in patients with non-small cell lung cancer. Methods: A total of 118 patients with non-small cell lung cancer were randomly divided into two groups of 59 patients. The control group was treated with conventional chemotherapy. The study group was given Qushi Decoction orally on the basis of the control group. The clinical efficacy and adverse reactions were compared between the two groups in terms of coagulation function (PT, Fib, BPC and APTT) .Results: After treatment, the levels of PT and APTT increased, while the levels of BPC and Fib decreased in the study group compared with those in the control group before and after treatment (P <0.05) .The improvement rate of clinical efficacy in the study group was 84.7% , Compared with 59.3% in the control group, the difference was statistically significant (P <0.05) .The gastrointestinal reaction rate and renal dysfunction rate in the study group were 44.1% and 3.4% respectively, while those in the control group were 71.2% and 15.3 %, Two groups, the difference was statistically significant (P <0.05) .Conclusion: Qu Yu Decoction treatment of non-small cell lung cancer patients can improve blood hypercoagulability, relieve clinical symptoms and reduce the incidence of side effects.